PDE5A and breast cancer: In addition to inhibitors of the canonical Wnt pathway, we identified four novel compounds that significantly affect the maintenance of ALDHhigh CSCs in SUM149 breast cancer cells, including the cyclic guanine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor MY5445.